Trial suggests metformin effective at reducing odds of serious outcomes for COVID-19 patients seeking early treatment

In work published in the New England Journal of Medicine, researchers—led by the University of Minnesota Medical School and School of Public Health—have found that metformin, a commonly prescribed diabetes medication lowers the odds of emergency department visits, hospitalizations, or death due to COVID-19 by over 40 percent—and over 50 percent if prescribed early in onset of symptoms. The study also found no positive effect from treatment with either ivermectin or low-dose fluvoxamine.